-
2
-
-
0000286732
-
A minute chromosome in human granulocytic leukemia
-
Nowell PC, Hungerford DA. A minute chromosome in human granulocytic leukemia. Science. 1960;132:1497-1497
-
(1960)
Science
, vol.132
, pp. 1497-1497
-
-
Nowell, P.C.1
Hungerford, D.A.2
-
3
-
-
0033614446
-
Medical Progress. Chronic myeloid leukemia
-
Sawyers CL. Medical Progress. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330-1340.
-
(1999)
N Engl J Med
, vol.340
, pp. 1330-1340
-
-
Sawyers, C.L.1
-
4
-
-
0015694748
-
A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining
-
Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290-293.
-
(1973)
Nature
, vol.243
, pp. 290-293
-
-
Rowley, J.D.1
-
5
-
-
0021802841
-
Fused transcript of abl and bcr genes in chronic myelogenous leukaemia
-
DOI 10.1038/315550a0
-
Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315:550-554. (Pubitemid 15021190)
-
(1985)
Nature
, vol.315
, Issue.6020
, pp. 550-554
-
-
Shtivelman, E.1
Lifshitz, B.2
Gale, R.P.3
Canaani, E.4
-
6
-
-
0025117392
-
Induction of chronic myelogenous leukemia in mice by the P210(bcr/abl) gene of the Philadelphia chromosome
-
Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824-830. (Pubitemid 20078558)
-
(1990)
Science
, vol.247
, Issue.4944
, pp. 824-830
-
-
Daley, G.Q.1
Van Etten, R.A.2
Baltimore, D.3
-
7
-
-
0025187837
-
Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL
-
Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR-ABL. Proc Natl Acad Sci U S A. 1990;87:6649-6653. (Pubitemid 20351538)
-
(1990)
Proceedings of the National Academy of Sciences of the United States of America
, vol.87
, Issue.17
, pp. 6649-6653
-
-
Kelliher, M.A.1
McLaughlin, J.2
Witte, O.N.3
Rosenberg, N.4
-
8
-
-
0029947186
-
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
-
DOI 10.1038/nm0596-561
-
Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566. (Pubitemid 26151518)
-
(1996)
Nature Medicine
, vol.2
, Issue.5
, pp. 561-566
-
-
Druker, B.J.1
Tamura, S.2
Buchdunger, E.3
Ohno, S.4
Segal, G.M.5
Fanning, S.6
Zimmermann, J.7
Lydon, N.B.8
-
9
-
-
33845444046
-
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
-
DOI 10.1056/NEJMoa062867
-
Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417. (Pubitemid 44903745)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.23
, pp. 2408-2417
-
-
Druker, B.J.1
Guilhot, F.2
O'Brien, S.G.3
Gathmann, I.4
Kantarjian, H.5
Gattermann, N.6
Deininger, M.W.N.7
Silver, R.T.8
Goldman, J.M.9
Stone, R.M.10
Cervantes, F.11
Hochhaus, A.12
Powell, B.L.13
Gabrilove, J.L.14
Rousselot, P.15
Reiffers, J.16
Cornelissen, J.J.17
Hughes, T.18
Agis, H.19
Fischer, T.20
Verhoef, G.21
Shepherd, J.22
Saglio, G.23
Gratwohl, A.24
Nielsen, J.L.25
Radich, J.P.26
Simonsson, B.27
Taylor, K.28
Baccarani, M.29
So, C.30
Letvak, L.31
Larson, R.A.32
more..
-
10
-
-
0033520092
-
Chronic myelogenous leukemia: Biology and therapy
-
Faderl S, Talpaz, Estrov Z, Kantarjian HM, et al. Chronic myelogenous leukemia. biology and therapy. Ann Int Med. 1999;131:207-219. (Pubitemid 29365004)
-
(1999)
Annals of Internal Medicine
, vol.131
, Issue.3
, pp. 207-219
-
-
Faderl, S.1
Talpaz, M.2
Estrov, Z.3
Kantarjian, H.M.4
-
11
-
-
33747154547
-
Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet
-
DOI 10.1182/blood-2006-02-005686
-
Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6):1809-1820. (Pubitemid 44394987)
-
(2006)
Blood
, vol.108
, Issue.6
, pp. 1809-1820
-
-
Baccarani, M.1
Saglio, G.2
Goldman, J.3
Hochhaus, A.4
Simonsson, B.5
Appelbaum, F.6
Apperley, J.7
Cervantes, F.8
Cortes, J.9
Deininger, M.10
Gratwohl, A.11
Guilhot, F.12
Horowitz, M.13
Hughes, T.14
Kantarjian, H.15
Larson, R.16
Niederwieser, D.17
Silver, R.18
Hehlmann, R.19
-
12
-
-
10744233716
-
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
-
DOI 10.1056/NEJMoa022457
-
O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004. (Pubitemid 36302244)
-
(2003)
New England Journal of Medicine
, vol.348
, Issue.11
, pp. 994-1004
-
-
O'Brien, S.G.1
Guilhot, F.2
Larson, R.A.3
Gathmann, I.4
Baccarani, M.5
Cervantes, F.6
Cornelissen, J.J.7
Fischer, T.8
Hochhaus, A.9
Hughes, T.10
Lechner, K.11
Nielsen, J.L.12
Rousselot, P.13
Reiffers, J.14
Saglio, G.15
Shepherd, J.16
Simonsson, B.17
Gratwohl, A.18
Goldman, J.M.19
Kantarjian, H.20
Taylor, K.21
Verhoef, G.22
Bolton, A.E.23
Capdeville, R.24
Druker, B.J.25
more..
-
13
-
-
33644538458
-
Beneficial effects of cytogenetic and molecular response on long term outcome in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with Imatinib (IM): Update from the IRIS study
-
on behalf of the IRIS study group. abstract. Abstract 166
-
Simonsson B, on behalf of the IRIS study group. Beneficial effects of cytogenetic and molecular response on long term outcome in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with Imatinib (IM): update from the IRIS study [abstract]. Blood. 2005;106:52a. Abstract 166.
-
(2005)
Blood
, vol.106
-
-
Simonsson, B.1
-
14
-
-
0021336851
-
Prognostic discrimination in "good-risk" chronic granulocytic leukemia
-
Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984;63:789-799.
-
(1984)
Blood
, vol.63
, pp. 789-799
-
-
Sokal, J.E.1
Cox, E.B.2
Baccarani, M.3
-
15
-
-
0037085785
-
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study
-
DOI 10.1182/blood.V99.6.1928
-
Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928-1937. (Pubitemid 34525471)
-
(2002)
Blood
, vol.99
, Issue.6
, pp. 1928-1937
-
-
Talpaz, M.1
Silver, R.T.2
Druker, B.J.3
Goldman, J.M.4
Gambacorti-Passerini, C.5
Guilhot, F.6
Schiffer, C.A.7
Fischer, T.8
Deininger, M.W.N.9
Lennard, A.L.10
Hochhaus, A.11
Ottmann, O.G.12
Gratwohl, A.13
Baccarani, M.14
Stone, R.15
Tura, S.16
Mahon, F.-X.17
Fernandes-Reese, S.18
Gathmann, I.19
Capdeville, R.20
Kantarjian, H.M.21
Sawyers, C.L.22
more..
-
16
-
-
11144354274
-
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia
-
DOI 10.1182/blood-2003-11-3800
-
Kantarjian, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004;103(8):2873-12778 (Pubitemid 38451654)
-
(2004)
Blood
, vol.103
, Issue.8
, pp. 2873-2878
-
-
Kantarjian, H.1
Talpaz, M.2
O'Brien, S.3
Garcia-Manero, G.4
Verstovsek, S.5
Giles, F.6
Rios, M.B.7
Shan, J.8
Letvak, L.9
Thomas, D.10
Faderl, S.11
Ferrajoli, A.12
Cortes, J.13
-
18
-
-
77953379757
-
First report of the TOPS study: A randomized phase III study of 400 mg vs 800 mg Imatinib in patients with newly diagnosed, previously untreated CML, in chronic phase using molecular end points
-
abstract. Abstract 402
-
Cortes J, Baccarani M, Guilhot F, et al. First report of the TOPS study: A randomized phase III study of 400 mg vs 800 mg Imatinib in patients with newly diagnosed, previously untreated CML, in chronic phase using molecular end points [abstract]. 13th Congress of European Hematological Association. Abstract 402.
-
13th Congress of European Hematological Association
-
-
Cortes, J.1
Baccarani, M.2
Guilhot, F.3
-
19
-
-
37849034132
-
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: The GIMEMA Working Party on CML
-
Palandri F. Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. J Clin Oncol. 2008;26(1):106-111.
-
(2008)
J Clin Oncol
, vol.26
, Issue.1
, pp. 106-111
-
-
Palandri, F.1
-
20
-
-
16844372957
-
Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials
-
abstract. Abstract 23
-
Silver RT, Talpaz M, Sawyers CL, et al. Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials [abstract]. Blood. 2004;104:11a Abstract 23.
-
(2004)
Blood
, vol.104
-
-
Silver, R.T.1
Talpaz, M.2
Sawyers, C.L.3
-
21
-
-
0037093092
-
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study
-
DOI 10.1182/blood.V99.10.3530
-
Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99(10):3530-3539. (Pubitemid 34534519)
-
(2002)
Blood
, vol.99
, Issue.10
, pp. 3530-3539
-
-
Sawyers, C.L.1
Hochhaus, A.2
Feldman, E.3
Goldman, J.M.4
Miller, C.B.5
Ottmann, O.G.6
Schiffer, C.A.7
Talpaz, M.8
Guilhot, F.9
Deininger, M.W.N.10
Fischer, T.11
O'Brien, S.G.12
Stone, R.M.13
Gambacorti-Passerini, C.B.14
Russell, N.H.15
Reiffers, J.J.16
Shea, T.C.17
Chapuis, B.18
Coutre, S.19
Tura, S.20
Morra, E.21
Larson, R.A.22
Saven, A.23
Peschel, C.24
Gratwohl, A.25
Mandelli, F.26
Ben-Am, M.27
Gathmann, I.28
Capdeville, R.29
Paquette, R.L.30
Druker, B.J.31
more..
-
22
-
-
0142243204
-
Chromosomal Abnormalities in Philadelphia Chromosome-Negative Metaphases Appearing during Imatinib Mesylate Therapy in Patients with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase
-
DOI 10.1002/cncr.11729
-
Medina J, Kantarjian H, Talpaz M, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer. 2003;98(9):1905-1911. (Pubitemid 37310233)
-
(2003)
Cancer
, vol.98
, Issue.9
, pp. 1905-1911
-
-
Medina, J.1
Kantarjian, H.2
Talpaz, M.3
O'Brien, S.4
Garcia-Manero, G.5
Giles, F.6
Rios, M.B.7
Hayes, K.8
Cortes, J.9
-
23
-
-
8644286697
-
Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib
-
DOI 10.1080/10428190410001723278
-
Loriaux M, Deininger M. Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. Leuk Lymphoma. 2004;45:2197-2203. (Pubitemid 39504313)
-
(2004)
Leukemia and Lymphoma
, vol.45
, Issue.11
, pp. 2197-2203
-
-
Loriaux, M.1
Deininger, M.2
-
24
-
-
4344638050
-
Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia
-
DOI 10.1038/sj.leu.2403399
-
Terre C, Eclache V, Rousselot P, et al. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia. 2004;18:1340-1346. (Pubitemid 39136741)
-
(2004)
Leukemia
, vol.18
, Issue.8
, pp. 1340-1346
-
-
Terre, C.1
Eclache, V.2
Rousselot, P.3
Imbert, M.4
Charrin, C.5
Gervais, C.6
Mozziconacci, M.J.7
Maarek, O.8
Mossafa, H.9
Auger, N.10
Dastugue, N.11
Talmant, P.12
Van Den Akker, J.13
Leonard, C.14
N'Guyen Khac, F.15
Mugneret, F.16
Viguie, F.17
Lafage-Pochitaloff, M.18
Bastie, J.N.19
Roux, G.L.20
Nicolini, F.21
Maloisel, F.22
Vey, N.23
Laurent, G.24
Recher, C.25
Vigier, M.26
Yacouben, Y.27
Giraudier, S.28
Vernant, J.P.29
Salles, B.30
Roussi, J.31
Castaigne, S.32
Leymarie, V.33
Flandrin, G.34
Lessard, M.35
more..
-
25
-
-
33947386190
-
Resistance to imatinib mesylate in chronic myeloid leukaemia
-
DOI 10.1016/j.canlet.2006.07.010, PII S0304383506004897
-
Melo JV, Chuah C. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett. 2007;249:121-132. (Pubitemid 46452920)
-
(2007)
Cancer Letters
, vol.249
, Issue.2
, pp. 121-132
-
-
Melo, J.V.1
Chuah, C.2
-
26
-
-
10744228340
-
Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: Results and prognostic factors for response and progression-free survival in 150 patients
-
Cervantes F, Hernandez-Boluda JC, Steegmann JL, et al; Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: Results and prognostic factors for response and progression-free survival in 150 patients. Haematologica. 2003;88:1117-1122. (Pubitemid 37362543)
-
(2003)
Haematologica
, vol.88
, Issue.10
, pp. 1117-1122
-
-
Cervantes, F.1
Hernandez-Boluda, J.-C.2
Steegmann, J.-L.3
Conde, E.4
Alvarez-Larran, A.5
Lopez-Jimenez, J.6
Osorio, S.7
Villalon, L.8
Camos, M.9
Garcia-Conde, J.10
Odriozola, J.11
-
27
-
-
0035885928
-
Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia
-
Huntly BJP, Reid AG, Bench AJ, Campbell LJ, Telford N, Shepherd P. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood. 2001;98:1732-1738.
-
(2001)
Blood
, vol.98
, pp. 1732-1738
-
-
Huntly, B.J.P.1
Reid, A.G.2
Bench, A.J.3
Campbell, L.J.4
Telford, N.5
Shepherd, P.6
-
28
-
-
33745085275
-
OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): Reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib
-
DOI 10.1182/blood-2005-11-4687
-
White DL, Saunders VA, Dang P, et al. OCT-1 mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN 107): reduced OCT 1 activity is the cause of low in vitro sensitivity to imatinib. Blood. 2006;108(2):697-704. (Pubitemid 44061372)
-
(2006)
Blood
, vol.108
, Issue.2
, pp. 697-704
-
-
White, D.L.1
Saunders, V.A.2
Dang, P.3
Engler, J.4
Zannettino, A.C.W.5
Cambareri, A.C.6
Quinn, S.R.7
Manley, P.W.8
Hughes, T.P.9
-
29
-
-
37049028176
-
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: Higher doses of imatinib may overcome the negative impact of low OCT-1 activity
-
DOI 10.1182/blood-2007-06-093617
-
White DL, Saunders VA, Dang P, et al. Most CML patients who have a sub optimal response to imatinib have low OCT-1 activity; higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 2007;110(12):4064-4072. (Pubitemid 350248463)
-
(2007)
Blood
, vol.110
, Issue.12
, pp. 4064-4072
-
-
White, D.L.1
Saunders, V.A.2
Dang, P.3
Engler, J.4
Venables, A.5
Zrim, S.6
Zannettino, A.7
Lynch, K.8
Manley, P.W.9
Hughes, T.10
-
30
-
-
33750077276
-
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
-
DOI 10.1038/sj.leu.2404318, PII 2404318
-
Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006;20:1767-1773. (Pubitemid 44574988)
-
(2006)
Leukemia
, vol.20
, Issue.10
, pp. 1767-1773
-
-
Jabbour, E.1
Kantarjian, H.2
Jones, D.3
Talpaz, M.4
Bekele, N.5
O'Brien, S.6
Zhou, X.7
Luthra, R.8
Garcia-Manero, G.9
Giles, F.10
Rios, M.B.11
Verstovsek, S.12
Cortes, J.13
-
31
-
-
33744461022
-
Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: A retrospective analysis from the French intergroup of CML
-
Nicolini FE, Corm S, Le QH, et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML. Leukemia. 2006;20:1061-1066.
-
(2006)
Leukemia
, vol.20
, pp. 1061-1066
-
-
Nicolini, F.E.1
Corm, S.2
Le, Q.H.3
-
32
-
-
10744232328
-
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
-
DOI 10.1182/blood-2002-09-2896
-
Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102:276-283. (Pubitemid 36759665)
-
(2003)
Blood
, vol.102
, Issue.1
, pp. 276-283
-
-
Branford, S.1
Rudzki, Z.2
Walsh, S.3
Parkinson, I.4
Grigg, A.5
Szer, J.6
Taylor, K.7
Herrmann, R.8
Seymour, J.F.9
Arthur, C.10
Joske, D.11
Lynch, K.12
Hughes, T.13
-
33
-
-
3142676436
-
Overriding imatinib resistance with a novel ABL kinase inhibitor
-
DOI 10.1126/science.1099480
-
Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399-401. (Pubitemid 38938156)
-
(2004)
Science
, vol.305
, Issue.5682
, pp. 399-401
-
-
Shah, N.P.1
Tran, C.2
Lee, F.Y.3
Chen, P.4
Norris, D.5
Sawyers, C.L.6
-
34
-
-
0037438467
-
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia
-
DOI 10.1182/blood-2002-05-1451
-
Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003;101:473-475. (Pubitemid 36077567)
-
(2003)
Blood
, vol.101
, Issue.2
, pp. 473-475
-
-
Kantarjian, H.M.1
Talpaz, M.2
O'Brien, S.3
Giles, F.4
Garcia-Manero, G.5
Faded, S.6
Thomas, D.7
Shan, J.8
Rios, M.B.9
Cortes, J.10
-
35
-
-
33745102555
-
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
-
DOI 10.1056/NEJMoa055229
-
Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinibresistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531-2541. (Pubitemid 43882349)
-
(2006)
New England Journal of Medicine
, vol.354
, Issue.24
, pp. 2531-2541
-
-
Talpaz, M.1
Shah, N.P.2
Kantarjian, H.3
Donato, N.4
Nicoll, J.5
Paquette, R.6
Cortes, J.7
O'Brien, S.8
Nicaise, C.9
Bleickardt, E.10
Blackwood-Chirchir, M.A.11
Iyer, V.12
Chen, T.-T.13
Huang, F.14
Decillis, A.P.15
Sawyers, C.L.16
-
36
-
-
33745086350
-
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
-
DOI 10.1056/NEJMoa055104
-
Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542-2551. (Pubitemid 43882350)
-
(2006)
New England Journal of Medicine
, vol.354
, Issue.24
, pp. 2542-2551
-
-
Kantarjian, H.1
Giles, F.2
Wunderle, L.3
Bhalla, K.4
O'Brien, S.5
Wassmann, B.6
Tanaka, C.7
Manley, P.8
Rae, P.9
Mietlowski, W.10
Bochinski, K.11
Hochhaus, A.12
Griffin, J.D.13
Hoelzer, D.14
Albitar, M.15
Dugan, M.16
Cortes, J.17
Alland, L.18
Ottmann, O.G.19
-
37
-
-
33747154547
-
Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet
-
DOI 10.1182/blood-2006-02-005686
-
Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809-1820. (Pubitemid 44394987)
-
(2006)
Blood
, vol.108
, Issue.6
, pp. 1809-1820
-
-
Baccarani, M.1
Saglio, G.2
Goldman, J.3
Hochhaus, A.4
Simonsson, B.5
Appelbaum, F.6
Apperley, J.7
Cervantes, F.8
Cortes, J.9
Deininger, M.10
Gratwohl, A.11
Guilhot, F.12
Horowitz, M.13
Hughes, T.14
Kantarjian, H.15
Larson, R.16
Niederwieser, D.17
Silver, R.18
Hehlmann, R.19
-
38
-
-
41349123259
-
Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: Practical advice on the use and interpretation of monitoring methods
-
Kantarjian H, Schiffer C, Jones D, Cortes J, et al. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood. 2008;111(4):1774-1780.
-
(2008)
Blood
, vol.111
, Issue.4
, pp. 1774-1780
-
-
Kantarjian, H.1
Schiffer, C.2
Jones, D.3
Cortes, J.4
-
39
-
-
33846925617
-
The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia
-
DOI 10.1182/blood-2006-06-031682
-
Oehler VG, Gooley T, Snyder DS, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood. 2007;109:1782-1789. (Pubitemid 46239615)
-
(2007)
Blood
, vol.109
, Issue.4
, pp. 1782-1789
-
-
Oehler, V.G.1
Gooley, T.2
Snyder, D.S.3
Johnston, L.4
Lin, A.5
Cummings, C.C.6
Chu, S.7
Bhatia, R.8
Forman, S.J.9
Negrin, R.S.10
Appelbaum, F.R.11
Radich, J.P.12
-
40
-
-
33846023983
-
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
-
DOI 10.1182/blood-2006-03-011239
-
Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007;109:58-60. (Pubitemid 46053043)
-
(2007)
Blood
, vol.109
, Issue.1
, pp. 58-60
-
-
Rousselot, P.1
Huguet, F.2
Rea, D.3
Legros, L.4
Cayuela, J.M.5
Maarek, O.6
Blanchet, O.7
Marit, G.8
Gluckman, E.9
Reiffers, J.10
Gardembas, M.11
Mahon, F.-X.12
-
41
-
-
0037186924
-
Imatinib mesylate - A new oral targeted therapy
-
DOI 10.1056/NEJMra013339
-
Savage DG, Antman KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med. 2002;346:683-693. (Pubitemid 34815874)
-
(2002)
New England Journal of Medicine
, vol.346
, Issue.9
, pp. 683-693
-
-
Savage, D.G.1
Antman, K.H.2
|